PHAR is proud to announce their sponsorship at Virtual ISPOR 2021 and will be hosting a virtual exhibit at the meeting. Registered attendees will be able to learn more about PHAR’s research and services and chat live with President Michael S. Broder, MD, MSHS, and Vice President, Mallik Greene, BPharm, PhD, DBA.
Archives for 2021
PHAR presented research on transthyretin-mediated (ATTR) amyloidosis and Huntington’s disease (HD) at the virtual 2021 Annual Meeting of the American Academy of Neurology. PHAR’s Sheila Reiss Reddy, PhD, RPh, Eunice Chang, PhD, and Marian Tarbox, MPP, in partnership with Akcea Therapeutics, Inc., investigated the feasibility of estimating ATTR amyloidosis prevalence and incidence using IBM® MarketScan® Commercial and Medicare databases. They also presented research on the clinical characteristics and resource use patterns among Medicare beneficiaries with ATTR amyloidosis in the years before diagnosis. In addition, PHAR’s Sheila Reiss Reddy, PhD, RPh, and Eunice Chang, PhD, in partnership with Genentech, Inc., presented their findings on healthcare resource use among US Medicare beneficiaries with late-onset HD. The posters for these studies can be found on the PHAR publications page, and the abstracts were published in Neurology’s April 2021 supplement issue.
PHAR’s Sheila Reiss Reddy, PhD, RPh, Eunice Chang, PhD, and Caleb Paydar, BS, in conjunction with Genentech, Inc., presented the results of two studies of Huntington’s disease in Medicaid beneficiaries. Their first study compared healthcare utilization and costs among US Medicaid beneficiaries with Huntington’s disease to those without Huntington’s disease. They also presented a study on the burden of illness among US Medicare beneficiaries with late-onset Huntington’s disease. The abstracts were published in the April 2021 supplement issue of the Journal of Managed Care & Specialty Pharmacy, and the posters can be found on the PHAR publications page.
Michael S. Broder, MD, MSHS, president of PHAR shares 5 numbers that will affect the pharmaceutical industry in 2021. Published on the HealthEconomics.com blog, his predictions span important domains such as COVID, politics, and future directions for health economics research. Read the post here, and reach out to let us know your thoughts.